RxDoctor Payments Data

Theresa Weber, MD

Neurology · Fredericksburg, TXNPI 1720048499

Payments from drug & device makers

$4,877in general payments, 2019–2025

Across 292 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$720
  • Teva Pharmaceuticals USA, Inc.$662
  • Acadia Pharmaceuticals Inc$444
  • Pfizer$348
  • Novartis$340
  • Neurocrine Biosciences, Inc.$233
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$4,75397%
  • Education$1243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,877 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$211,147
Medicare patients
435
Services billed
9,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab14$122,298
CopaxoneGlatiramer Acetate20$115,172
NuplazidPimavanserin Tartrate15$108,798
Nurtec OdtRimegepant Sulfate56$86,735
UbrelvyUbrogepant49$53,235
QuliptaAtogepant25$40,426
Emgality PenGalcanezumab-Gnlm31$38,558
BriviactBrivaracetam23$29,501
BotoxOnabotulinumtoxina26$29,491
RexultiBrexpiprazole17$24,325
Aimovig AutoinjectorErenumab-Aooe19$19,533
Galantamine ErGalantamine Hbr102$8,844
Memantine Hcl ErMemantine Hcl117$8,281
Chlorpromazine Hcl12$7,354
Rivastigmine46$7,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$720$123,153100 claims
Teva Pharmaceuticals USA, Inc.Copaxone$662$115,17220 claims
Acadia Pharmaceuticals IncNuplazid$444$108,79815 claims
PfizerNurtec Odt$348$86,73556 claims
UCB, Inc.Briviact$112$29,50123 claims
Otsuka America Pharmaceutical, Inc.Rexulti$60$24,32517 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$63$5,95111 claims
Lilly USA, LLCOlanzapine$87$1,54817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,246 neurology providers in Texas.

Other neurology in Fredericksburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →